Related Experiment Video
Updated: Jun 16, 2026
14:06
Detection of Rare Genomic Variants from Pooled Sequencing Using SPLINTER
Published on: June 23, 2012
Comparative performance of gene-based warfarin dosing algorithms in a multiethnic population.
S A Lubitz1, S A Scott, E B Rothlauf
1Zena and Michael Wiener Cardiovascular Institute, Mount Sinai School of Medicine, New York, NY, USA. slubitz@partners.org
Journal of Thrombosis and Haemostasis : JTH
|February 5, 2010
Summary
Gene-based warfarin dosing algorithms show limited generalizability in diverse populations. Additional clinical factors and genetic variants did not improve dose prediction accuracy in this study.
Area of Science:
- Pharmacogenomics
- Clinical Pharmacology
- Genetics
Background:
- Warfarin dosing algorithms based on genes were developed in limited populations.
- Their applicability to diverse ethnic groups is not well-established.
Purpose of the Study:
- To evaluate existing warfarin dosing algorithms in a multiethnic cohort.
- To determine if adding clinical variables or new genetic markers improves algorithm performance.
Main Methods:
- Compared predicted vs. actual warfarin doses in 145 patients using 12 algorithms.
- Algorithms included CYP2C9 and VKORC1 variants.
- Tested additional factors: race, concurrent medications, CYP4F2, CALU, GGCX variants.
Main Results:
- Gene-based algorithms explained 37-55% of warfarin dose variability.
- Race, concurrent medications, or interacting medications did not improve predictions.
- CYP4F2, CALU, or GGCX variants did not enhance algorithm accuracy.
Conclusions:
- Current gene-based warfarin dosing algorithms have moderate predictive power in diverse populations.
- Additional clinical and genetic factors did not significantly improve dose prediction in this cohort.
Related Concept Videos
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:27Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:27Principles of Pharmacogenetics: Types of Genetic Variants
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...